B of A Securities Maintains Neutral on Beta Bionics, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 67.3%

Neg 67.3% Neu 0% Pos 0%

B of A Securities analyst Travis Steed maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the price target from $23 to $11.